Lentiviral vector ramp-up: J&J and Legend to invest $500M in New Jersey manufacturing to support Carvykti

Zachary Brennan

Senior Editor

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lentiviral vector ramp-up: J&J and Legend to invest $500M in New Jersey manufacturing to support Carvykti

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lentiviral vector ramp-up: J&J and Legend to invest $500M in New Jersey manufacturing to support Carvykti